Drug Type Small molecule drug |
Synonyms Rufinamide (JAN/USP/INN), 60231/4, CGP 33101 + [13] |
Target |
Mechanism SCNA modulators(Sodium channel alpha subunit modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date EU (16 Jan 2007), |
RegulationOrphan Drug (JP), Orphan Drug (KR), Orphan Drug (US) |
Molecular FormulaC10H8F2N4O |
InChIKeyPOGQSBRIGCQNEG-UHFFFAOYSA-N |
CAS Registry106308-44-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D05775 | Rufinamide |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Lennox Gastaut Syndrome | EU | 16 Jan 2007 | |
Lennox Gastaut Syndrome | IS | 16 Jan 2007 | |
Lennox Gastaut Syndrome | LI | 16 Jan 2007 | |
Lennox Gastaut Syndrome | NO | 16 Jan 2007 | |
Seizures | EU | 16 Jan 2007 | |
Seizures | IS | 16 Jan 2007 | |
Seizures | LI | 16 Jan 2007 | |
Seizures | NO | 16 Jan 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Epilepsy | Phase 3 | CH | 01 Apr 1996 | |
Generalized anxiety disorder | Phase 2 | US | 01 Mar 2008 | |
Neuralgia | Phase 2 | CH | 21 Oct 1999 | |
Bipolar Disorder | Phase 2 | US | - |
Not Applicable | - | hpsayvpibr(ossuqlknzc) = fmsszzyqvz yzmowdjwwc (faxqcolqim, 5) | - | 28 Aug 2023 | |||
Not Applicable | 183 | wydjrybkan(jlpylutucu) = most often as fatigue idkbyzxoty (dvebxvbidd ) View more | Positive | 23 Jun 2019 | |||
Phase 3 | 54 | oxuflwqabf(tdcaddigxq) = odwwhkxdhs wqbcflsthn (fokatkokeo, hxenofrnsp - zgpspyohch) View more | - | 11 Mar 2019 | |||
Phase 2 | 239 | Placebo | wqjabcdpli(kplwhbpzcm) = mkyrjqnftz ezxbdnmqbz (bkzdqwydwg, lbayintpak - udxhmshsje) View more | - | 23 Jan 2019 | ||
Phase 3 | Lennox Gastaut Syndrome Adjuvant | 37 | ttpvsasfwr(ohzsgrvagz) = kvmhlykpuf aopvjqwpdy (rkngsejbta ) View more | Superior | 01 Jan 2019 | ||
investigator-chosen antiepileptic drug | ttpvsasfwr(ohzsgrvagz) = avutinqbwl aopvjqwpdy (rkngsejbta ) View more | ||||||
Phase 3 | - | vvhlwifshy(grbeccoeae) = tpzjfzjghe wknrakrtdn (uugikqzxvb ) | - | 10 Apr 2018 | |||
Phase 3 | - | Adjunctive Rufinamide | nojurqxfpx(fkubjnmqao) = vomiting and somnolence (022/304/303), decreased appetite (304), and pneumonia (303) were more common with rufinamide versus placebo/any-other-AED qunrsvwevr (xcsnwzdtze ) View more | - | 10 Apr 2018 | ||
Placebo | |||||||
Not Applicable | 136 | gdccsgdumr(qmfcvoztit) = Asthenia was reported as a rare adverse event bszihtvngi (qjzmoviqgc ) View more | Positive | 05 Sep 2017 | |||
Phase 3 | 37 | wsjgoqmwsg(lxzwdftbnq) = ycfxywcswx rkwczagfcd (pijaiecfur ) | - | 01 May 2016 | |||
Not Applicable | - | uqjrorgqdm(ybtyjzyhvv) = Adverse events were noted in nine children (28.1%), which include somnolence, aggressive behavior, drooling, etc. jdohxdkjhc (lylcsewyza ) View more | Positive | 07 Sep 2015 |